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METHODOLOGY
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Abstract 
Background: The FluoroSpot assay, an advancement of the ELISpot assay, enables simultaneous measurement of 
different analytes secreted at a single-cell level. This allows parallel detection of several cytokines secreted by immune 
cells upon antigen recognition. Easier standardization, higher sensitivity and reduced labour intensity render FluoroS-
pot assays an interesting alternative to flow-cytometry based assays for analysis of clinical samples. While the use of 
immunoassays to study immunological primary and secondary endpoints becomes increasingly attractive, assays 
used require pre-trial validation. Here we describe the assay validation (precision, specificity and linearity) of a FluoroS-
pot immunological endpoint assay detecting Interferon γ (IFNγ) and Interleukin 2 (IL2) for use in clinical trial immune 
monitoring.
Methods: We validated an IFNγ/IL2 FluoroSpot assay to determine Epstein-Barr virus (EBV)-specific cellular immune 
responses (IFNγ, IL2 and double positive IFNγ + IL2 responses), using overlapping peptide pools corresponding to 
EBV-proteins BZLF1 and EBNA3A. Assay validation was performed using cryopreserved PBMC of 16 EBV-seropositive 
and 6 EBV-seronegative donors. Precision was assessed by (i) testing 16 donors using three replicates per assay (intra-
assay precision/repeatability) (ii) using two plates in parallel (intermediate precision/plate-to-plate variability) and (iii) 
by performing the assays on three different days (inter-assay precision/reproducibility). In addition, we determined 
specificity, linearity and quantification limits of the assay. Further we tested precision across the two assay systems, 
IFNγ/IL2 FluoroSpot and the corresponding enzymatic single cytokine ELISpot.
Results: The validation revealed: (1) a high intra-assay precision (coefficient of variation (CV) 9.96, 8.85 and 13.05 %), 
intermediate precision (CV 6.48, 10.20 and 12.97 %) and reproducibility (CV 20.81 %, 12,75 % and 12.07 %) depending 
on the analyte and antigen used; (2) a specificity of 100 %; (3) a linearity with R2 values from 0.93 to 0.99 depending 
on the analyte. The testing of the precision across the two assay systems, adduced a concordance correlation coef-
ficient pc = 0.99 for IFNγ responses and pc = 0.93 for IL2 responses, indicating a large agreement between both assay 
methods.
Conclusions: The validated primary endpoint assay, an EBV peptide pool specific IFNγ/IL2 FluoroSpot assay was 
found to be suitable for the detection of EBV-specific immune responses subject to the requirement of standardized 
assay procedure and data analysis.
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Background
The enzyme-linked immuno spot (ELISpot) assay, which 
enumerates peripheral blood mononuclear cells releas-
ing cytokines upon specific antigen stimulation, has 
become an assay of choice for evaluation of cell-mediated 
immune responses in many clinical trials [1–3].
The ELISpot assay is limited, however, in that only one 
cytokine at a time can be assessed. The FluoroSpot assay, 
an advancement of the ELISpot assay, enables simul-
taneous measurement of different analytes secreted at 
a single-cell level [4, 5]. This facilitates the detection of 
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polyfunctional T cells, which have been suggested to be 
correlates of protection in various infectious diseases [6–
8]. By detecting different cytokines with a specific fluo-
rophore and analyzing differentially fluorescent spots by 
specific filter systems, cells producing single or multiple 
cytokines can be identified. FluoroSpot assays maintain 
the simplicity and sensitivity of the ELISpot assay but 
offer the advantage of multiplex analyses.
Investigating antigen specific immune responses as a 
primary endpoint in clinical trials requires highly sen-
sitive and validated assays to determine immune cell 
reactivity ex  vivo correlating with clinical outcome. 
Assays for detecting cellular immune responses in 
humans have already been used to determine primary 
endpoints in clinical trials [9, 10], but the validation of 
these assays has often not been approached in a manner 




Validation is a well-known process in industry, but is 
much less common for immune monitoring assays used 
in the academic and clinical settings with only few pub-
lished guidelines, especially for validation of assays that 
are considered to be “state-of-art” [12–15]. Since 2005, 
two consortia have performed proficiency panel experi-
ments to address T cell immunoassay harmonization 
and as a consequence the MIATA (“Minimum Infor-
mation About T-cell Assays”) initiative was launched 
to optimize assay performance and reproducibility 
between different laboratories [16–18]. Implementa-
tion of cross-laboratory validation is known to support 
reduction of data variability, thus guaranteeing consist-
ency of datasets generated by different clinical trials 
sites [19–21].
Guidelines for assay validation define eight parameters 
that must be investigated in order to validate a bioanalyt-
ical assay [22]: (1) specificity, (2) accuracy, (3) precision 
(repeatability, intermediate precision, reproducibility), 
(4) detection limit, (5) quantification limit, (6) linearity, 
(7) range and (8) robustness. Here we provide, to our 
knowledge, the first validation report for an IFNγ/IL2 
FluoroSpot assay designed to allow qualitative and quan-
titative evaluation of cellular immune responses. Further 
we tested precision across the two related assay systems, 
IFNγ/IL2 FluoroSpot and the corresponding enzymatic 
single cytokine ELISpot.
As a result, the validated primary endpoint assay, an 
Epstein-Barr virus (EBV) peptide pool specific IFNγ/IL2 
FluoroSpot assay was found to be suitable for the detec-
tion of EBV-specific immune responses in a clinical trial 
setting.
Methods
The authors acknowledge the concept of the MIATA 
framework which was recently published [17, 18]. There-
fore, detailed information is provided as structured in the 




Peripheral blood was taken by venipuncture from 30 
healthy donors (20 women, 10 men) with an average age 
of 30 years (range 17–50 years). Donors were either EBV-
seropositive or EBV-seronegative, diagnosed by pre-test-
ing with a diagnostic assay. A pre-screening of donors for 
EBV-specific cell-mediated immune responses was done 
by ELISpot analyses prior to the FluoroSpot validation 
experiments, to ensure an inclusion of a broad range of 
EBV-specific low- and high-responders. Informed con-
sent was obtained from all participating subjects prior to 
their inclusion in this validation experiments.
Cryoconservation of PBMC
Within 4  h after collection of heparinized whole blood 
human peripheral blood mononuclear cells (PBMC) 
were separated by Ficoll density gradient (human Pan-
coll, PAN-BIOTECH, Aidenbach, Germany) using 50 ml 
LeucosepTM tubes (Greiner Bio-One, Frickenhausen) and 
washed one time with sterile phosphate buffered saline 
(PBS) (Life Technologies, Darmstadt, Germany) and once 
with RPMI1640 medium (Life Technologies, Invitrogen, 
Darmstadt, Germany) following our established standard 
operating procedure (SOP). Trypan blue (Life Technolo-
gies, Darmstadt, Germany) staining was used to count on 
living cells. The median PBMC number obtained per ml 
whole blood was 0.7x106 PBMC. PBMC were frozen at 
5 × 106 PBMC per vial in 1.8 ml cryotubes (Thermo Sci-
entific, Roskilde, Denmark) in a concentration of 1 × 107 
PBMC per 1 ml freezing medium (fetal calf serum (FCS) 
(Life Technologies, Darmstadt, Germany) supplemented 
with 10 % dimethyl sulfoxide (Sigma-Aldrich, Steinheim, 
Germany) using a freezing container (Mr. Frosty, Thermo 
Scientific, Roskilde, Denmark) and put on −80 °C. After 
24  h PBMC were stored in liquid nitrogen until further 
use.
Thawing and resting of PBMC
According to our SOP, PBMC were thawed at 37  °C 
using Roswell Park Memorial Institute (RPMI1640) 
medium supplemented with 10 % FCS and 1 % penicil-
lin–streptomycin (PenStrep, Life Technologies, Invitro-
gen, Darmstadt, Germany) (abbr.: RPMI-10). After two 
washing steps with RPMI-10, cells were counted with 
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an automated cell counter (Vi-cell XR, Beckman Coul-
ter, Krefeld, Germany). The median cell recovery after 
thawing was 5.0  ×  106 PBMC per vial with a median 
viability of 93  %. For a standard resting procedure 
PBMC were incubated for 18 h at 37 °C in a humidified 
atmosphere at 5  % CO2 at a concentration of 2 ×  106 
PBMC/ml RPMI-10. After resting the median cell 




The following stimulatory agents were used in this study: 
Overlapping peptide pools of EBV-derived proteins 
BZLF1 (59 peptides) and EBNA3A (234 peptides) (JPT 
Peptide Technologies, Berlin, Germany), consisting of 
15mers overlapping 11 amino acids in a concentration of 
1 µg/ml. The optimal assay concentration of both peptide 
pools was identified in previous titration experiments. 
Phytohemagglutinin (PHA-L) (Sigma-Aldrich Chemie, 
Schnelldorf, Germany) was used as a mitogen for stim-
ulation in a concentration of 2  µg/ml. All experiments 
were performed in triplicates when cells were stimu-
lated with antigen (BZLF1, EBNA3A) or in six replicates 
for the PHA-L-stimulated cells. RPMI-10 was added as 
a negative control in triplicates and anti-CD3 (in a dilu-
tion of 1:1000, mAb CD3-2, Mabtech AB, Nacka Strand, 
Sweden) was used as a positive control in a single well for 
each donor.
IFNγ/IL2 FluoroSpot assay
IFNγ/IL2 FluoroSpot assays (human IFNγ/IL2 FluoroS-
pot Kit with pre-coated plates, product code: FSP-0102-
10, Mabtech AB, Nacka Strand, Sweden) were performed 
according to the manufacturer´s instructions, except for 
washing steps, which were increased to a seven-time 
washing. Either 2  ×  105 PBMC/well for BZLF1- and 
EBNA3A-stimulated PBMC or 5  ×  104 PBMC/well for 
PHA-L-stimulated PBMC were plated in a final volume 
of 150 µl/well.
ELISpot assays
IFNγ ELISpot assays (human IFNγ ELISpotPLUS Kit 
with pre-coated plates, product code: 3420-4APW-10, 
Mabtech AB, Nacka Strand, Sweden) and IL2 ELIS-
pot assays (human IL2 ELISpotPLUS Kit with pre-coated 
plates, product code: 3445-4APW-10, Mabtech AB, 
Nacka Strand, Sweden) were performed according to the 
manufacturer´s instructions, except for washing steps, 
which were increased to a seven-time washing. 2 × 105 
PBMC/well were plated in a final volume of 150 µl/well 
and stimulated with peptide pools of EBV-derived pro-
teins BZLF1 or EBNA3A, respectively.
Data acquisition
ELISpot and FluoroSpot plates were evaluated within 
3 days after assay performance using an automated reader 
system (CTL-ImmunoSpot® S6 Ultra-V Analyzer/CTL 
ImmunoSpot 5.1 Professional DC Software, CTL Europe, 
Bonn, Germany). ELISpot plates were scanned with 
automatically adjusted settings conducted by the reader. 
Solely the selection of the plate type and the centring of 
the wells were done manually. FluoroSpot plates were 
scanned with manual settings for both fluorophore filters 
(fluorescein isothiocyanate (FITC)/phycoerythrin (PE)) 
by adjusting the gain and exposure time of the UV-light. 
Counting of spot forming cells (SFC) within ELISpot and 
FluoroSpot plates was performed manually in compli-
ance with the guidelines for the automated evaluation of 
ELISpot assays [23] and our laboratory standard count-
ing parameters consisting of a best possible spot separa-
tion, a spot size gating from minimum to maximum and 
a counting mask size of 90 %. Spot counts were normal-
ized to 100 % of the well area. The settings for sensitivity 
of spot counting were established and adjusted manually 
for each plate using antigen stimulated and negative con-
trol wells. In detail, the sensitivity for the counting of sin-
gle spots was adjusted by identifying antigen-stimulated 
wells with spots that were well distributed and clearly dis-
tinguishable from background activity and artefacts. In a 
next step, the selected parameters for the sensitivity of 
counting spots were checked on negative control wells to 
prevent to count on small background spots. If necessary, 
the parameters for the sensitivity of counting spots were 
adjusted to exclude artefact or background spots. The 
performed adjustments were rechecked on the antigen-
stimulated wells and if necessary adapted another time 
to make sure to count on the most distinct spots. This 
way of parameter checking was repeated on other sets of 
antigen-stimulated and negative control wells. If possible, 
throughout the counting procedure of one single plate, 
similar settings were used for replicates of one donor, and 
one antigen. All obtained counts were reviewed and cer-
tified by a second person during a quality control process 
including an exclusion of artefacts within wells or a rejec-
tion of failed wells. Figure  1 displays an image example 
of representative data sets obtained using the IFNγ/IL2 
FluoroSpot assay in which cryopreserved PBMC of an 
EBV-seropositive donor were stimulated with the BZLF1 
peptide pool.
Interpretation of results
Final results are represented as spot forming cells (SFC) 
per 2 × 105 PBMC for BZLF1- and EBNA3A-stimulated 
PBMC and 5 × 104 PBMC for PHA-L-stimulated PBMC. 
Unless specified differently, denoted results represent 
background subtracted data. The median background 
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reactivity (spot counts in negative control wells) observed 
within the ELISpot assay was 0 spots per well (range 0–4 
SFC/well) in IFNγ ELISpot assays and 5 spots per well 
(range 0–19 SFC/well) in IL2 ELISpot assays. For the 
IFNγ/IL2 FluoroSpot assays we observed a median back-
ground of 1 spot per well (range 0–4 SFC/well) for single 
positive IFNγ responses (IFNγ), 5 spots per well (range 
1–10 SFC/well) for single positive IL2 responses (IL2) 
and 1 spots per well (range 0–2 SFC/well) for double pos-
itive IFNγ +  IL2 responses (IFNγ +  IL2). Positive reac-
tivity to experimental stimulatory agents was selected 
as a p-value of equal or smaller than 0.05 when apply-
ing the distribution free sampling method (DFR(2x)), 
by using a web-based tool (http://www.scharp.org/zoe/
runDFR/) [24], which compares the spot counts in anti-
gen stimulated wells with spot counts in negative con-
trol wells. In addition, only mean spot counts of at least 
11 SFC/2 × 105 PBMC (in EBV peptide pool stimulated 
wells) or 11 SFC/5  ×  104 PBMC (in PHA-L-stimulated 
wells) were regarded as a positive reactivity. Outliers of 
the replicates, predefined as results which originate from 
irregular wells, were excluded during quality control. 
Raw data of all performed assays can be provided upon 
request.
Laboratory environment
All experiments were performed by well-trained mem-
bers of the lab in accordance with our established SOP 
protocols. Laboratory personnel participated regularly in 
external international ELISpot proficiency panels.
Statistical analyses
To define assay precision, the coefficient of varia-
tion (%CV) was calculated as the ratio of the standard 
deviation to the mean and expressed as a percentage 
value. All tests were two-sided and were conducted on 
exploratory 5  % significance levels. Effect measures are 
presented with 95 % confidence intervals. Linear regres-
sion analysis was performed to assess the coefficient of 
determination R2. The concordance correlation coeffi-
cient pc by Lin [25] was calculated to investigate agree-
ment of measurements. Likewise, the Bland–Altman 
method was used to assess the agreement between 
FluoroSpot and ELISpot measurements by calculating 
the average difference d (FluoroSpot-ELISpot) and the 
95  % limits of agreement (d  ±  1.96 standard deviation 
(s) of the difference) [26]. The software Graph Pad Prism 
5.00 (GraphPad Software, La Jolla, California, USA) and 
R (http://www.r-project.org/) [27] were used for statisti-
cal analyses.
Results
First we evaluated assay precision, including repeatabil-
ity (intra-assay precision), intermediate precision (plate-
to-plate variability) and reproducibility of the assay (day 
to day variability). For the complete validation process 
cryopreserved PBMC of one isolation batch were used 
to assess assay precision using the same lot of assay rea-
gents. All samples were assayed in triplicates (BZLF1 and 
EBNA3A) or six replicates (PHA-L; control antigen).
Intra‑assay precision
We used PBMC of 16 donors to examine intra-assay 
precision of the IFNγ/IL2 FluoroSpot assay. Overall we 
determined a high intra-assay precision for IFNγ, IL2 and 
IFNγ  +  IL2 responses for both, the EBV-derived anti-
gens and the mitogen. Regarding all donors, a mean CV 
of 9.96, 8.85 and 13.05 % was obtained for IFNγ, IL2 and 
Fig. 1 Illustration of IFNγ/IL2 FluoroSpot assay images. Individual images were captured for IFNγ (left image) (FITC filter) and IL2 (central image) (PE 
filter) and used to generate the computerized overlay of the two filters showing double positive IFNγ + IL2 cell responses (right image). IFNγ, IL2 
and IFNγ + IL2 secreting cells upon stimulation with BZLF1 are depicted as green (left image), red (central image), and yellow (right image) spots, 
respectively
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IFNγ + IL2 responses, respectively (Table 1A–C). These 
results indicate that intra-assay variability was accept-
able. It also justified the analysis of samples with lower 
replicates when clinical material is limited.
Inter‑assay precision
To evaluate inter-assay variability we used PBMC of eight 
donors plated into two different assay plates in parallel. 
Inter-assay precision of the two assays performed on the 
same day showed low inter-plate variability. The mean 
CV for all tested donors was 6.48, 10.20 and 12.97  % 
for IFNγ, IL2 and IFNγ  +  IL2 responses, respectively 
(Table 2A–C).
We assessed inter-assay variability also in assays per-
formed on three consecutive days (i.e. reproduc-
ibility) using PBMC of ten donors. The mean CV was 
20.81, 12.75 and 12.07  % for IFNγ, IL2 and IFNγ +  IL2 
responses, respectively (Table  3A–C). The inter-assay 
testing revealed that inter-day variability was only 
slightly higher than the inter-plate variability for IL2 and 
IFNγ + IL2 responses. The CV for IFNγ responses, how-
ever, was clearly higher when we performed the assay at 
different days, but still acceptable.
Concerning the obtained CVs for low counts of 
cytokine secreting cells one should keep in mind, that for 
mathematical reasons, high CV values tend to be deter-
mined when spot numbers are of low frequency.
Next, we analyzed the sensitivity of the assay and deter-
mined its quantitative range and linearity.
Limit of detection
The limit of detection (LOD) of the ELISpot/FluoroSpot 
assay is defined as the lowest number of spots that is pre-
cisely distinguishable from an unstimulated control well 
(O) with LOD = O +  2SD of O [11, 28]. For the IFNγ/
IL2 FluoroSpot assay we determined mean background 
levels of 2 SFC/well (range 0–4, SD 1.37), 5 SFC/well 
(range 1–10, SD 2.53) and 1 SFC/well (range 0–2, SD 
0.54) for IFNγ, IL2, and IFNγ +  IL-2 responses, respec-
tively (Additional file 1: Table S1). Based on these results 
and in line with the determined LLOQ (lower limit of 
quantification) we set a consistent LOD for the IFNγ/IL2 
FluoroSpot assay at 10 SFC/2x105 PBMC.
Lower limit of quantification
To specify the lower limit of quantification (LLOQ), 
which is defined as the lowest value that can be quanti-
tatively determined with acceptable precision and accu-
racy [13], of the IFNγ/IL2 FluoroSpot assay we analyzed 
the intra-assay CV of antigen-specific IFNγ, IL2 and 
IFNγ  +  IL2 responses of donors with numbers of SFC 
ranging between 1–10 SFC/well. We calculated an intra-
assay CV of 46.28, 43.48 and 69.74 % for IFNγ, IL2 and 
IFNγ  +  IL2 responses, respectively (Additional file  2: 
Table S2a–c). These results indicate that SFC counts 
below 11 SFC/well are of low precision, but it should 
be taken into account that the high variability in low 
counts expressed as CV, could be a result of the math-
ematical equation of the CV, which presents the ratio 
of the standard deviation to the mean. In contrast, SFC 
counts of “low responders” ranging between 11–50 SFC/
well revealed an acceptable intra-assay CV (<25  %) of 
10.70, 9.29 and 16.13  % for IFNγ, IL2, and IFNγ +  IL2 
responses, respectively (Additional file  3: Table S3a–c). 
In line with these observations, we set the LLOQ for the 
IFNγ/IL2 FluoroSpot assay to 11 SFC/well.
Upper limit of quantification
The automated reader system we used is able to count 
SFC numbers up to approximately 1000 SFC per well. 
Intra-assay variability of those high SFC numbers is still 
acceptable (%CV  <  25; data not shown), the setting of 
counting parameters, however, is difficult, because fusion 
of several adjacent single spots results in spot aggregates. 
We used cryopreserved PBMC of six donors to deter-
mine the upper limit of quantification (ULOQ), which 
is defined as the highest value that can be quantitatively 
determined with acceptable precision and accuracy [11]. 
All samples were stimulated with PHA-L and assayed in 
six replicates. Based on the morphology and the ability 
to count on clearly separated single spots we defined the 
ULOQ of an IFNγ/IL2 FluoroSpot assay as 700 SFC/well 
(data not shown). Magnitude of EBV-specific responses 
was always below this ULOQ.
Linearity
To determine linearity of the IFNγ/IL2 FluoroSpot 
assay we tested PBMC of two different donors in six 
replicates using cell numbers of 1.25  ×  104, 2.5  ×  104, 
5 ×  104 and 1 ×  105/well. PBMC were stimulated with 
the mitogen PHA-L, to ensure adequate numbers of IL2-
secreting cells. Stimulating PBMC with peptide pools of 
EBV-derived proteins BZLF1 and EBNA3A did not reveal 
high enough frequencies of IL2-secreting cells to assess 
linearity of the IFNγ/IL2 FluoroSpot assay.
For both donors we observed a linear relationship for 
IFNγ (R2 =  0.99, respectively), IL2 (R2 =  0.98 and 0.93, 
respectively), and IFNγ  +  IL2 responses (R2  =  0.99, 
respectively) (Fig. 2). These results suggest that the analy-
sis of less cells per well is feasible, when clinical material 
is limited. The authors recommend, however, re-assessing 
linearity using the IFNγ/IL2 FluoroSpot assay for clinical 
trial monitoring. A lower cell concentration can only be 
recommended if an appropriate cell-to-cell contact (e.g. 
in a smaller well format (384 well plate)) and an effective 
way of antigen presentation is ensured, and a true linear 
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Table 1 Intra-assay variability of IFNγ, IL2 and IFNγ + IL2 responses in the IFNγ/IL2 FluoroSpot assay
Donor Antigen Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6 Mean SD %CV
A
 S09 BZLF1 283 267 280 ND ND ND 277 8.50 3.07
 S11 BZLF1 432 440 493 ND ND ND 455 33.15 7.29
 S14 BZLF1 438 452 479 ND ND ND 456 20.84 4.57
 S16 BZLF1 458 374 384 ND ND ND 405 45.88 11.32
 S18 BZLF1 110 148 103 ND ND ND 120 24.21 20.12
 S01 EBNA3A 30 26 31 ND ND ND 29 2.65 9.12
 S10 EBNA3A 28 31 31 ND ND ND 30 1.73 5.77
 S12 EBNA3A 38 43 46 ND ND ND 42 4.04 9.55
 S20 EBNA3A 68 60 81 ND ND ND 70 10.60 15.21
 S21 EBNA3A 166 158 192 ND ND ND 172 17.78 10.34
 S12 PHA-L 35 35 45 44 Rejected 38 39 4.83 12.25
 S15 PHA-L 718 659 774 685 679 Rejected 703 45.01 6.40
 S21 PHA-L Rejected 715 836 740 786 771 770 46.20 6.00
 S25 PHA-L 293 326 391 250 276 Rejected 307 54.37 17.70
 S26 PHA-L 98 120 123 Rejected 98 123 112 13.20 11.75
 S27 PHA-L 253 280 284 264 226 Rejected 261 23.38 8.95
Mean 22.27 9.96
B
 S09 BZLF1 63 67 52 ND ND ND 61 7.77 12.80
 S11 BZLF1 28 27 30 ND ND ND 28 1.53 5.39
 S14 BZLF1 37 31 34 ND ND ND 34 3.00 8.82
 S16 BZLF1 39 39 43 ND ND ND 40 2.31 5.73
 S18 BZLF1 32 37 37 ND ND ND 35 2.89 8.17
 S01 EBNA3A 33 29 21 ND ND ND 28 6.11 22.08
 S10 EBNA3A 26 26 20 ND ND ND 24 3.46 14.43
 S12 EBNA3A 47 44 51 ND ND ND 47 3.51 7.42
 S20 EBNA3A 41 32 Rejected ND ND ND 37 6.36 17.44
 S21 EBNA3A 42 38 38 ND ND ND 39 2.31 5.87
 S12 PHA-L 142 148 143 142 112 Rejected 137 14.42 10.49
 S15 PHA-L 718 645 647 718 652 Rejected 676 38.43 5.68
 S21 PHA-L Rejected 685 688 693 725 700 698 16.02 2.29
 S25 PHA-L 413 410 408 382 Rejected 412 405 13.00 3.21
 S26 PHA-L 488 505 511 554 501 524 514 22.96 4.47
 S27 PHA-L 374 423 430 445 385 383 407 29.59 7.28
Mean 10.85 8.85
C
 S09 BZLF1 50 51 57 ND ND ND 53 3.79 7.19
 S11 BZLF1 19 18 21 ND ND ND 19 1.53 7.90
 S14 BZLF1 24 18 18 ND ND ND 20 3.46 17.32
 S16 BZLF1 26 23 26 ND ND ND 25 1.73 6.93
 S18 BZLF1 23 29 29 ND ND ND 27 3.46 12.83
 S01 EBNA3A 18 11 11 ND ND ND 13 4.04 30.31
 S10 EBNA3A 13 18 11 ND ND ND 14 3.61 25.75
 S12 EBNA3A 23 25 27 ND ND ND 25 2.00 8.00
 S20 EBNA3A 10 14 16 ND ND ND 13 3.06 22.91
 S21 EBNA3A 22 17 21 ND ND ND 20 2.65 13.23
 S12 PHA-L 0 0 0 0 0 0 0 – –
 S15 PHA-L Rejected 317 372 345 363 Rejected 349 24.25 6.94
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Table 1 continued
Donor Antigen Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6 Mean SD %CV
 S21 PHA-L Rejected 460 454 437 Rejected 489 460 21.65 4.71
 S25 PHA-L 113 118 124 Rejected 125 Rejected 120 5.60 4.66
 S26 PHA-L 66 79 89 68 70 93 78 11.43 14.75
 S27 PHA-L 175 181 200 189 142 Rejected 177 21.89 12.34
Mean 7.61 13.05
Values represent the number of detected antigen-specific IFNγ (A), IL2 (B) and IFNγ + IL2 (C) SFC/2 × 105 PBMC (stimulated with 1 µg/ml BZLF1 or EBNA3A peptide 
pools) or mitogen-specific IFNγ (A), IL2 (B) and IFNγ + IL2 (C) SFC/5 × 104 PBMC (stimulated with 2 µg/ml PHA-L) in the IFNγ/IL2 FluoroSpot assay (data is not 
background subtracted); “rejected” wells were not accepted because they did not pass the quality control
ND not done, SD standard deviation, CV coefficient of variation
Table 2 Inter-assay variability of IFNγ, IL2 and IFNγ + IL2 responses in the IFNγ/IL2 FluoroSpot assay
Values represent the mean number of antigen-specific IFNγ (A), IL2 (B) and IFNγ + IL2 (C) SFC/2 × 105 PBMC (stimulated with 1 µg/ml BZLF1 or EBNA3A peptide 
pools) or mitogen-specific IFNγ (A), IL2 (B) and IFNγ + IL2 (C) SFC/2 × 105 PBMC/5 × 104 PBMC (stimulated with 2 µg/ml PHA-L) detected in two different assay plates 
performed on the same day in parallel
SD standard deviation, CV coefficient of variation
Donor Antigen Plate 1 Plate 2 Plate 1 and plate 2
Mean Mean Mean SD % CV
A
 S09 BZLF1 274 233 254 28.99 11.44
 S11 BZLF1 317 326 322 6.36 1.98
 S12 EBNA3A 92 94 93 1.41 1.52
 S13 EBNA3A 65 63 64 1.41 2.21
 S15 PHA-L 645 680 663 24.75 3.74
 S21 PHA-L 668 753 711 60.10 8.46
 S25 PHA-L 234 287 261 37.48 14.39
 S26 PHA-L 214 240 227 18.38 8.10
Mean 22.36 6.48
B
 S09 BZLF1 56 47 52 6.36 12.36
 S11 BZLF1 52 86 69 24.04 34.84
 S12 EBNA3A 33 35 34 1.41 4.16
 S13 EBNA3A 0 0 0 – –
 S15 PHA-L 575 657 616 57.98 9.41
 S21 PHA-L 698 691 695 4.95 0.71
 S25 PHA-L 411 403 407 5.66 1.39
 S26 PHA-L 547 617 582 49.50 8.50
Mean 21.42 10.20
C
 S09 BZLF1 52 49 51 2.12 4.20
 S11 BZLF1 61 85 73 16.97 23.25
 S12 EBNA3A 19 28 24 6.36 27.08
 S13 EBNA3A 0 0 0 – –
 S15 PHA-L 329 349 339 14.14 4.17
 S21 PHA-L 453 459 456 4.24 0.93
 S25 PHA-L 86 105 96 13.44 14.07
 S26 PHA-L 102 130 116 19.80 17.07
Mean 11.01 12.97
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correlation between the plated cell number and the spot 
number exists.
Diagnostic specificity and sensitivity
Among donors with confirmed positive EBV-serosta-
tus the EBV-specific IFNγ/IL2 FluoroSpot was positive 
in all 16/16 donors (diagnostic sensitivity: 100  %) with 
mean frequencies of BZLF1- and EBNA3A-specific T 
cells ranging from 11–411 SFC/2 × 105 PBMC (median 
90 SFC/2 × 105 PBMC) and 12–167 SFC/2 × 105 PBMC 
(median 54 SFC/2 × 105 PBMC), respectively (Additional 
file 4: Table S4).
An EBV-specific IFNγ/IL2 FluoroSpot assay with 
PBMC of the control group (n  =  6 EBV-seronegative 
donors) was negative (Additional file 4: Table S4). This 
result proved a specificity of the EBV-specific IFNγ/
Table 3 Inter-day variability of IFNγ, IL2, IFNγ + IL2 responses in the IFNγ/IL2 FluoroSpot assay
Values represent the mean number of antigen-specific IFNγ (A), IL2 (B) and IFNγ + IL2 (C) SFC/2 × 105 PBMC (stimulated with 1 µg/ml BZLF1 or EBNA3A peptide pools) 
or mitogen-specific IFNγ (A), IL2 (B) and IFNγ + IL2 (C) SFC/2 × 105 PBMC/5 × 104 PBMC (stimulated with 2 µg/ml PHA-L) detected on three different assay plates 
performed on three consecutive days
SD standard deviation, CV coefficient of variation
Donor Antigen Day 1 Day 2 Day 3 Mean SD %CV
A
 S09 BZLF1 191 145 149 162 25.48 15.76
 S11 BZLF1 326 344 351 340 12.90 3.79
 S14 BZLF1 223 161 175 186 32.52 17.45
 S18 BZLF1 257 194 189 213 37.90 17.77
 S10 EBNA3A 27 27 19 24 4.62 18.98
 S12 EBNA3A 92 44 35 57 30.64 53.76
 S19 EBNA3A 144 127 67 113 40.45 35.90
 S15 PHA-L 304 358 311 324 29.37 9.05
 S25 PHA-L 77 88 60 75 14.11 18.81
 S26 PHA-L 214 242 297 251 42.23 16.82
Mean 27.02 20.81
B
 S09 BZLF1 69 62 67 66 3.61 5.46
 S11 BZLF1 18 20 17 18 1.53 8.33
 S14 BZLF1 48 57 62 56 7.09 12.74
 S18 BZLF1 27 29 48 35 11.59 33.43
 S10 EBNA3A 17 18 15 17 1.53 9.17
 S12 EBNA3A 33 34 29 32 2.65 8.27
 S19 EBNA3A 17 12 20 16 4.04 24.74
 S15 PHA-L 492 615 572 560 62.42 11.15
 S25 PHA-L 344 359 348 350 7.77 2.22
 S26 PHA-L 521 617 662 600 72.02 12.00
Mean 17.42 12.75
C
 S09 BZLF1 69 56 63 63 6.51 10.38
 S11 BZLF1 20 19 18 19 1.00 5.26
 S14 BZLF1 54 60 54 56 3.46 6.19
 S18 BZLF1 32 32 42 35 5.77 16.34
 S10 EBNA3A 14 13 13 13 0.58 4.33
 S12 EBNA3A 19 26 20 22 3.79 17.47
 S19 EBNA3A 12 11 14 12 1.53 12.39
 S15 PHA-L 215 276 258 250 31.34 12.55
 S25 PHA-L 50 59 47 52 6.24 12.01
 S26 PHA-L 95 130 155 127 30.14 23.79
Mean 9.04 12.07
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IL2 FluoroSpot assay of 100 %, thus allowing the analy-
sis of EBV-specific immune responses in a clinical trial 
setting.
Precision across assays: FluoroSpot vs. ELISpot assay
Finally we tested the concordance between the two 
assay systems by determining numbers of IFNγ- and 
IL2-secreting cells in the FluoroSpot- and the corre-
sponding single cytokine ELISpot assay. We used cryo-
preserved PBMC of ten and eight donors to examine 
number of IFNγ and IL2 secreting cells, respectively. 
PBMC stimulated with BZLF1 or EBNA3A were assayed 
in triplicates.
Calculating the concordance of the two assay systems 
we obtained a mean difference d between the two assay 
systems of d  =  1.95 SFC/2  ×  105 PBMC (95  % limits 
of agreement: −7.80 to 11.70) for IFNγ responses and 
d = −0.13 SFC/2 × 105 PBMC (95 % limits of agreement: 
−9.10 to 8.85) for IL2 responses with a concordance cor-
relation coefficient pc = 0.99 and pc = 0.93, respectively 
(Fig. 3), indicating that both assay methods give congru-
ent results.
Discussion
Although assay validation is a time consuming process it 
is a prerequisite for valid clinical trial monitoring using 
immunoassays (i.e. ELISpot, FluoroSpot or flow-cytom-
etry-based assays). Following the guidelines for assay 
validation [22], we determined specificity, precision, 
detection limit, quantification limit and linearity of an 
IFNγ/IL2 FluoroSpot assay.
ELISpot assays are very well-suited for high-through-
put analyses and have become a standard technique to 
assess T cell responses within a clinical trial setting [29, 
30]. The applicability of the assay system in clinical prac-
tice has been confirmed with the approval of a diagnostic 
a
b
Fig. 2 Linearity of the IFNγ/IL2 FluoroSpot assay. Magnitude of IFNγ, 
IL2, and IFNγ + IL2 responses of donor S25 (a) and S26 (b) within 
the IFNγ/IL2 FluoroSpot assay as a function of cell density. Depicted 
are the number of mitogen-specific IFNγ, IL2 and IFNγ + IL2 SFC/
well after stimulation with 2 µg/ml PHA-L; SFC spot forming cells. 
R2 = coefficient of determination
a
b
Fig. 3 Precision across assays: FluoroSpot vs. ELISpot assay. Concord-
ance between numbers of antigen-specific (BZLF1 and EBNA3A 
peptide pools) IFNγ- (a) and IL2 (b) SFC/2x105 PBMC detected within 
the IFNγ/IL2 FluoroSpot assay and an enzymatic IFNγ and IL2 ELISpot 
assay. Plotted is the difference in IFNγ (a) and IL2 (b) SFC/2x105 
PBMC detected after ex vivo restimulation with BZLF1 (black circle) or 
EBNA3A (red triangle) peptide pools within the FluoroSpot- or ELISpot 
assay plotted against the average of IFNγ or IL2 SFC detected in either 
of the two assays. Concordance between FluoroSpot and ELISpot 
results was assessed using the concordance correlation coefficient 
pc by Lin. Descriptive statistics are the average difference d (hori-
zontal solid line) and the limits of agreement (d ± 1.96 × s) (dashed 
line) of the detected T cell responses of both assay systems. d bias 
of measurements; s standard deviation; pc concordance correlation 
coefficient by Lin
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ELISpot for the detection of latent tuberculosis infection 
and disease [31]. Assay performance and data analysis is 
less time-consuming compared to flow cytometry-based 
assays (e.g. intracellular cytokine staining). In addition, 
assay performance can readily be standardized, validated 
according to international guidelines [11], and quality-
controlled in internationally conducted proficiency pan-
els [32, 33] (http://www.proficiencypanel.com/).
A major limitation of the ELISpot assay is its restriction 
to single parameter analyses. Several studies showed that 
immune monitoring using single cytokine detection is 
insufficient to provide an overall assessment of the T cell 
response and that the identification of protective func-
tional immune signatures requires polyfunctional analy-
sis [34]. Multiparametric FluoroSpot, an advancement of 
the ELISpot assay, allows the simultaneous assessment of 
multiple parameters in one well. Currently commercially 
available FluoroSpot assays are restricted to a maximum 
of three parameters, but technically up to six parameters 
are possible.
Some studies have demonstrated that ELISpot assays 
have a higher CV for intra- and inter-assay precision 
compared with flow cytometry-based assays (e.g. intra-
cellular cytokine staining, ICS) [35]. In our hands, ELIS-
pot and ICS show a relatively high level of concordance 
with comparable CV values [36], but we did not test 
whether this applies also to the IFNγ/IL2 FluoroSpot 
assay. International proficiency panels have shown that 
ELISpot assays give reproducible results among differ-
ent laboratories and the inter-laboratory CV was found 
to be less than 20 % [37, 38]. For the IFNγ/IL2 FluoroSpot 
assay we showed intra- and inter-assay precision with CV 
values clearly within this acceptable level.
Linearity is another important aspect of cell-based 
immunoassay validation [35]. The IFNγ/IL2 FluoroSpot 
assay showed a high linearity upon mitogen stimulation 
of PBMC, offering the possibility of using reduced cell 
numbers per well. But the minimal applicable number 
of cells per well must be adjusted for each antigen to the 
expected frequency of responding cells which may be 
present at or near the assay detection limit. In addition 
a check of assay linearity with the respective stimulating-
antigen is always required, due to the need for optimal 
cell-to-cell contact (with e.g. antigen-presenting cells) for 
sufficient stimulation.
Evaluating the limits of detection and quantification 
is important when establishing the parameters of an 
acceptable positive immune response [39]. Theoreti-
cally the detection limit of an ELISpot/FluoroSpot assay 
is extremely low, but due to a high variability at lower 
concentrations, the detection limit may not be accurate. 
In contrast, the lowest limit of quantification (LLOQ) 
is the lowest concentration that can be defined with 
highest accuracy and precision. It is often postulated 
that the detection limit of the ELISpot//FluoroSpot assay 
can be as low as 1/100,000 cells, thus at least ten times 
lower than ICS [40]. Our results show, however, that CV 
values are unacceptably high when dealing with these 
low frequencies of antigen-specific cells. Nonetheless, 
one should be aware that high variability in low counts 
expressed by the CV, could be a result of the mathemati-
cal equation of the CV, which presents the standard devi-
ation to the mean. For the IFNγ/IL2 FluoroSpot assay we 
determined a detection limit of 0.005 % which is similar 
to the LLOQ we determined in previous validation stud-
ies for the ELISpot and ICS and what has been reported 
by others [24].
To address the diagnostic specificity and diagnostic 
sensitivity of the IFNγ/IL2 FluoroSpot assay for use in 
an envisaged clinical trial setting we determined these 
parameters in an existing cohort of individuals with con-
firmed positive or negative EBV-serostatus. Both speci-
ficity and sensitivity was very high, proving the assay very 
suitable for monitoring in a clinical trial setting as it ful-
fills the acceptance criteria for biomarker [11] assays.
Finally, we also compared precision across two assay 
systems, the IFNγ/IL2 FluoroSpot assay and the corre-
sponding enzymatic single cytokine ELISpot assay. We 
obtained very high concordance between the results of 
the two assays with an equivalent sensitivity (concord-
ance correlation coefficient pc =  0.99 and pc =  0.93 for 
IFNγ and IL2 responses, respectively) as already reported 
by others [41]. This allows for comparability of already 
existing ELISpot-based data (e.g. from previous trial 
monitoring) with data obtained with the more advanced 
IFNγ/IL2 FluoroSpot assay.
In summary, the IFNγ/IL2 FluoroSpot assay showed 
high precision in combination with very high sensitivity 
and specificity. The broad linear range allows for more 
flexible specimen volume and permits analysis of fewer 
cells per assay when clinical material is limited. The 
IFNγ/IL2 FluoroSpot assay passed all validation checks 
and is suitable for the detection of EBV-specific immune 
responses in a clinical trial setting.
Conclusions
Investigating antigen specific immune responses as a pri-
mary endpoint in clinical trials requires highly sensitive 
and validated assays to determine immune cell reactivity 
ex  vivo correlating with clinical outcome. The FluoroS-
pot assay enables simultaneous analysis of single cells 
secreting multiple cytokines thus overcoming an impor-
tant current limitation of single color enzymatic ELISpot 
assays. The FluoroSpot assay allows monitoring of poly-
functional T cells, which have been suggested to be cor-
relates of protection in various infectious diseases. Our 
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data show that the validated primary endpoint assay, an 
IFNγ/IL2 FluoroSpot assay is suitable for the detection of 
EBV-specific immune responses in a clinical trial setting, 
subject to the requirement of standardized assay proce-
dure and data analysis.
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